Mr Keith Dionne

KANDO id: 88654

Bio

Keith Dionne joined Third Rock Ventures in 2011. As an EIR, he provides strategic input on new and existing portfolio companies with a particular focus on rare genetic diseases and novel biologics. Keith is an industry veteran with 20 years of experience leading U.S. and international biotechnology companies. Prior to joining Third Rock, Keith served as CEO at Surface Logix, Inc. Before that, he was the president and CEO of Alantos Pharmaceuticals, leading the company's acquisition by Amgen for more than $300 million in July 2007. Prior to joining Alantos, Keith was with Millennium Pharmaceuticals, Inc., where he held positions of increasing responsibility, concluding his seven-year tenure as both vice president of research and development strategy and vice president and general manager, technology business. Before his tenure with Millennium, Keith served as head of pre- clinical research & development, implants at ALZA Pharmaceuticals. Keith was one of four original scientists at CytoTherapeutics, Inc ., a cell transplantation company. He has served as an adjunct professor in the Biomedical Department at Brown University. Keith received both his Ph.D. in chemical engineering and his M.S. in the program for technology policy from Massachusetts Institute of Technology.

Career


Third Rock Ventures LLC

Venture capital firm focused on building healthcare companies

Education